Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 8/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22419572 | 0.93 | HTR6 (0.39) | NAMPTKIF11HTR6 | |
| SCHEMBL12467840 | 0.83 | NAMPT (0.57) | NAMPT | |
| SCHEMBL16107643 | 0.75 | SRC (0.57) | NAMPT | |
| SCHEMBL16108640 | 0.75 | SRC (0.56) | NAMPT | |
| SCHEMBL24332742 | 0.71 | SRC (0.55) | PKM | |
| SCHEMBL12467155 | 0.70 | NAMPT (0.76) | NAMPT | |
| SCHEMBL20953244 | 0.69 | CNR1 (0.43) | NAMPT | |
| SCHEMBL21524229 | 0.67 | NAMPT (0.54) | NAMPT | |
| SCHEMBL21524233 | 0.67 | NAMPT (0.53) | NAMPT | |
| SCHEMBL20953342 | 0.66 | NAMPT (0.55) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | NAMPT 1/4885PKM 941/4885TSHR 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.